A review of descending pain modulation in humans - Top-Institutions - MDSpire

A review of descending pain modulation in humans

  • By

  • Christopher D’Souza

  • Eden Brander-Whittingham

  • Shima Hassanpour

  • Brieana Keast

  • Jessica Merletti

  • Matthew Kong

  • Hannan Algitami

  • Patrick Stroman

  • June 4, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital/Harvard Medical School
    Massachusetts General Hospital/Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Pain Medicine
    • Neurology
    • Neurosurgery

  • #2

    Stanford University/Stanford Health Care
    Stanford University/Stanford Health Care

    Stanford, California

    Key Differentiators

    • Pain Medicine
    • Psychology

  • #3

    American Academy of Pain Medicine (AAPM)
    American Academy of Pain Medicine (AAPM)

    Chicago, Illinois

    Key Differentiators

    • Pain Medicine

  • #4

    Morristown Medical Center
    Morristown Medical Center

    Morristown, New Jersey

    Key Differentiators

    • Pain Medicine
    • Neuromodulation

  • #5

    MIT Hacking Medicine
    MIT Hacking Medicine

    Cambridge, Massachusetts

    Key Differentiators

    • Healthcare Innovation

Original Source(s)

A review of descending pain modulation in humans

  • by Christopher D’Souza, Eden Brander-Whittingham, Shima Hassanpour, Brieana Keast, Jessica Merletti, Matthew Kong, Hannan Algitami, Patrick Stroman

  • June 4, 2026

Related Content

Integrating multi-omics and machine learning to explore the role of amino acid metabolism in intervertebral disk degeneration

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

PT vs CBT for Chronic Low Back Pain

Sequential, multiple-assignment randomized trial compares stage I and stage II nonpharmacologic treatments over 52 weeks.